Shares of HLS Therapeutics Inc. (OTCMKTS:HLTRF – Get Free Report) dropped 0.3% during trading on Wednesday . The stock traded as low as $3.43 and last traded at $3.43. Approximately 100 shares changed hands during mid-day trading, a decline of 92% from the average daily volume of 1,181 shares. The stock had previously closed at $3.44.
HLS Therapeutics Stock Performance
The company has a 50-day moving average of $3.60 and a 200-day moving average of $3.71.
HLS Therapeutics Company Profile
HLS Therapeutics is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription products for niche therapeutic markets. Headquartered in Mississauga, Ontario, the company builds its portfolio through strategic licensing agreements and in-house development, with an emphasis on therapies that address unmet needs in neurology and rare disorders.
The company’s marketed offering includes treatments for neurological conditions, most notably primary periodic paralysis, for which it commercializes dichlorphenamide (Keveyis) in North America.
See Also
- Five stocks we like better than HLS Therapeutics
- If You Keep Cash In A U.S. Bank Account… Read This NOW
- Do not delete, read immediately
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Trump Devises the Death of the IRS ☠️
- Buy this $2 Gold Stock Before January 1, 2026
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
